Skip to main content
The Egyptian Heart Journal

Table 2 NYHA classification of the study population before and after sacubitril/valsartan combination medication commencement

From: Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)

Study population

Before S/V therapy

Six months after S/V therapy

Test value

p-value

NYHA class

NYHA class 1

13/100 (13.0%)

30/100 (30.0%)

9.728*

0.008

NYHA class 2

55/100 (55.0%)

50/100 (50.0%)

NYHA class 3

32/100 (32.0%)

20/100 (20.0%)

  1. NYHA Class, New York Heart association classification
  2. *Chi-square test
Back to article page